The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.

March 4 (Reuters) - Moderna shares rose ⁠9% ⁠on Wednesday after it settled ⁠a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to focus on its ‌pipeline. Analysts noted ...

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies. The recognition highlights

Inovio Pharmaceuticals and Novavax stocks pare back earlier gains as the rally loses enthusiasm.

Jan 12 (Reuters) - Moderna said on Monday ‌it expects to report around $1.9 billion in ‌sales for 2025, putting it near the upper end of its previously projected $1.6 billion to $2 billion forecast but well below revenue levels achieved ...

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer.

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to

Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial stages, with potential public health benefits but years from availability.

The biotech company has a pre-clinical program with the U.S. Army and a vaccine center at a Korean university. An American citizen on Sunday takes photos on his phone after he was evacuated from the MV Hondius in Tenerife, which is part of Spain's Canary ...

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.